Also considered
17 papers judged, 2 emailed ยท Read the digest →
Large multi-center registry analysis (SURROC-CON, n>3000) in recurrent epithelial ovarian cancer, published in Int J Gynecol Cancer, evaluating outcomes after secondary cytoreductive surgery versus chemotherapy alone. Supports secondary cytoreduction (with complete clearance) as associated with substantially better survival, reinforcing patient selection criteria including BRCA status for surgical candidacy in recurrent disease.
Randomized phase 1b/2 trial (OPAL cohort C) in Gynecologic Oncology comparing neoadjuvant niraparib monotherapy versus platinum-taxane chemotherapy in newly diagnosed HRD-positive advanced ovarian cancer. Niraparib produced a lower pre-surgery response rate than chemotherapy, informing whether PARP-inhibitor monotherapy could replace standard neoadjuvant chemotherapy in this population.
Biomarker analysis from clinical trials of the WEE1 inhibitor azenosertib in recurrent high-grade serous ovarian cancer, published in JCO Precision Oncology. Shows ctDNA-based molecular response (TP53 VAF decline) correlates with radiographic response and time to progression, supporting its use as an early efficacy readout in future trials.
Retrospective real-world cohort study (ESME database) in platinum-resistant high-grade ovarian carcinoma, published in Int J Gynecol Cancer, comparing chemotherapy regimens with/without bevacizumab. Suggests paclitaxel-based regimens may outperform gemcitabine or PLD, informing chemotherapy backbone choice in this setting but based on non-randomized data with modest sample size.
Narrative review of resistance mechanisms and emerging therapies in advanced epithelial ovarian cancer, published in Cancers (Basel). Summarizes the state of targeted, immune, and novel therapeutic strategies to inform understanding of the evolving treatment landscape.
Bayesian segregation analysis study in JCO Precision Oncology estimating age-specific ovarian cancer risk in PALB2 germline pathogenic variant carriers. Provides risk data relevant to genetic counseling and screening decisions rather than therapy selection.
Systematic review in Cancers (Basel) synthesizing phase I-III trial data on tisotumab vedotin monotherapy and combination regimens in advanced/recurrent cervical cancer. Supports its role as an effective antibody-drug conjugate option, including improved overall survival versus chemotherapy in phase 3 data, informing treatment choice in this setting.
Preclinical translational study in ovarian cancer cell lines and xenografts, published in Oncology Research, showing miR-320e overexpression enhances olaparib sensitivity via PI3K-AKT-mTOR pathway inhibition. Mechanistic findings suggest a potential biomarker/therapeutic strategy to overcome PARP inhibitor resistance but lack clinical outcome validation.
Preclinical xenograft study in Clinical Cancer Research testing an actinium-225-labeled anti-MUC-16 radioimmunoconjugate in ovarian and pancreatic cancer models. Shows durable tumor regression in mouse models, informing future clinical development of MUC-16-targeted radioligand therapy but with no patient data yet.
Preclinical/translational study in Molecular Carcinogenesis identifying FAM3C as a driver of ovarian cancer progression and olaparib resistance via HIF-1ฮฑ/STAT3 signaling, using cell line and xenograft models. Suggests a potential biomarker and therapeutic target for PARP-inhibitor resistance, but lacks patient-cohort validation linking FAM3C to olaparib outcomes.
Translational single-cell and proteomic study in J Immunother Cancer characterizing how ascites reprograms NK/innate lymphoid cells in high-grade serous ovarian cancer. Provides mechanistic insight into immune evasion but does not link findings to a specific therapy decision, limiting immediate clinical impact.
Single-arm phase 2 basket trial of T-DM1 in HER2-amplified advanced solid tumors (including lung, colorectal, and endometrial cohorts), published in Clinical Cancer Research. Shows variable response rates across tumor types, suggesting potential for HER2-directed therapy in select HER2-amplified cancers outside breast/gastric, though responses were modest in most non-salivary cohorts.
Multi-country retrospective real-world survey (n>3000) in BRCA wild-type/HRD-negative advanced ovarian cancer, published in Cancers, describing wide variation in first-line maintenance strategy (bevacizumab, PARP inhibitor, or surveillance) across five European countries. Highlights practice-pattern heterogeneity but does not provide comparative efficacy data to guide choice.
Retrospective real-world cohort study in advanced pMMR endometrial cancer treated with pembrolizumab-lenvatinib, published in Current Oncology. Suggests a baseline inflammatory index (SII) may help predict progression-free survival and toxicity, but is small and hypothesis-generating, requiring prospective validation.
Single-institution retrospective cohort of platinum-resistant ovarian cancer patients treated with mirvetuximab soravtansine, published in Int J Gynecol Cancer, characterizing folate receptor-alpha co-expression with other biomarkers and exploratory survival outcomes by subgroup. Findings are largely descriptive/correlative rather than establishing a new actionable biomarker-driven treatment decision.
Retrospective single-institution cohort study of endometrial cancer patients receiving chemotherapy, published in Gynecologic Oncology. Finds a high rate of venous thromboembolism, especially in advanced-stage disease, highlighting an opportunity for better VTE risk assessment in this population.
AJCC staging protocol update (version 9) for vulvar carcinoma, published in CA Cancer J Clin, aligning with 2021 FIGO staging changes. Revises T/N/M subcategories, which may affect stage-based treatment classification though it is primarily a staging rather than treatment guideline.